TrialLung cancer (Amsterdam, Netherlands)2018

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

David E Gerber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.